Asynt Launches Baffled Lab Reactor System
For a wide range of exothermic and large-scale reactions, Asynt’s ReactoMate Baffled Controlled Lab Reactor system has been shown to improve reproducibility of results, increase selectivity and reduce potentially unwanted side reactions as a result of its ability to provide fast mixing and dispersion.
By using specially designed PTFE baffle blades together with a PTFE turbine stirrer, Asynt is now able to offer scientists a new version of their 5000 mL ReactoMate Controlled Lab Reactor system, which is built to mix reactions more quickly and effectively. Most reaction vessels used by research chemists employ simple anchor or turbine stirring devices, both of which move liquid very well but usually this is in a circular direction with a vortex created in the centre. Despite this mixing looking dramatic the time for reactants to mix/disperse homogeneously with anchor or turbine stirrers is relatively slow.
This may not be an issue when the reaction under study is slow and non-exothermic however exothermic reactions such as hydrogenation, nitration, polymerisation, acid / base neutralisation and catalysis, especially those that require efficient cooling, can be seriously affected by slow dispersion during reagent addition. Similarly many reactions that work well in a lab flask often, when scaled up above 1000 mL, can also suffer seriously from this dispersion issue.
In addition to the new 5000 mL system, Asynt offers a special reactor lid, baffles and stirrer for customers to upgrade their existing suitable reaction vessels. Other size ReactoMate Baffled Controlled Lab Reactor systems are available as custom orders.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.